Dario Palmieri

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2776554/publications.pdf Version: 2024-02-01



DADIO PALMIEDI

#	Article	IF	CITATIONS
1	HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. Cancer Cell, 2006, 9, 459-471.	16.8	226
2	miR-130a targets MET and induces TRAIL-sensitivity in NSCLC by downregulating miR-221 and 222. Oncogene, 2012, 31, 634-642.	5.9	181
3	Protective role of miR-155 in breast cancer through <i>RAD51</i> targeting impairs homologous recombination after irradiation. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 4536-4541.	7.1	181
4	Oncosuppressive role of p53â€induced miRâ€205 in triple negative breast cancer. Molecular Oncology, 2012, 6, 458-472.	4.6	142
5	Altered MicroRNA Expression Profile in Human Pituitary GH Adenomas: Down-Regulation of miRNA Targeting HMGA1, HMGA2, and E2F1. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1128-E1138.	3.6	136
6	In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation. Journal of Experimental Medicine, 2013, 210, 951-968.	8.5	121
7	HMGA Proteins Up-regulate <i>CCNB2</i> Gene in Mouse and Human Pituitary Adenomas. Cancer Research, 2009, 69, 1844-1850.	0.9	107
8	Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 8573-8578.	7.1	105
9	miR-15b/16-2 deletion promotes B-cell malignancies. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 11636-11641.	7.1	98
10	Downregulation of HMGA-targeting microRNAs has a critical role in human pituitary tumorigenesis. Oncogene, 2012, 31, 3857-3865.	5.9	82
11	HMGA proteins promote ATM expression and enhance cancer cell resistance to genotoxic agents. Oncogene, 2011, 30, 3024-3035.	5.9	71
12	miR-302b enhances breast cancer cell sensitivity to cisplatin by regulating E2F1 and the cellular DNA damage response. Oncotarget, 2016, 7, 786-797.	1.8	70
13	HMGA2: A pituitary tumour subtype-specific oncogene?. Molecular and Cellular Endocrinology, 2010, 326, 19-24.	3.2	58
14	<i>Hmga1/Hmga2</i> double knock-out mice display a "superpygmy―phenotype. Biology Open, 2014, 3, 372-378.	1.2	54
15	Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer. Lung Cancer, 2019, 132, 72-78.	2.0	54
16	Human anti-nucleolin recombinant immunoagent for cancer therapy. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 9418-9423.	7.1	53
17	PATZ1 interacts with p53 and regulates expression of p53-target genes enhancing apoptosis or cell survival based on the cellular context. Cell Death and Disease, 2013, 4, e963-e963.	6.3	49
18	The cAMP-HMGA1-RBP4 system: a novel biochemical pathway for modulating glucose homeostasis. BMC Biology, 2009, 7, 24.	3.8	47

DARIO PALMIERI

#	Article	IF	CITATIONS
19	Cancer-Derived Extracellular Vesicle-Associated MicroRNAs in Intercellular Communication: One Cell's Trash Is Another Cell's Treasure. International Journal of Molecular Sciences, 2019, 20, 6109.	4.1	47
20	cMyc/miR-125b-5p Signalling Determines Sensitivity to Bortezomib in Preclinical Model of Cutaneous T-Cell Lymphomas. PLoS ONE, 2013, 8, e59390.	2.5	46
21	Regulation of microRNA expression by HMGA1 proteins. Oncogene, 2009, 28, 1432-1442.	5.9	44
22	PATZ1 acts as a tumor suppressor in thyroid cancer via targeting p53-dependent genes involved in EMT and cell migration. Oncotarget, 2015, 6, 5310-5323.	1.8	44
23	MicroRNAs for the Diagnosis and Management of Malignant Pleural Mesothelioma: A Literature Review. Frontiers in Oncology, 2018, 8, 650.	2.8	40
24	SOM230, A New Somatostatin Analogue, Is Highly Effective in the Therapy of Growth Hormone/Prolactin-Secreting Pituitary Adenomas. Clinical Cancer Research, 2007, 13, 2738-2744.	7.0	39
25	Quaking and <i>miR-155</i> interactions in inflammation and leukemogenesis. Oncotarget, 2015, 6, 24599-24610.	1.8	37
26	PIT1 upregulation by HMGA proteins has a role in pituitary tumorigenesis. Endocrine-Related Cancer, 2012, 19, 123-135.	3.1	34
27	Tumor Suppressor Role of the <i>CL2/DRO1/CCDC80</i> Gene in Thyroid Carcinogenesis. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2834-2843.	3.6	33
28	The impairment of the High Mobility Group A (HMGA) protein function contributes to the anticancer activity of trabectedin. European Journal of Cancer, 2013, 49, 1142-1151.	2.8	31
29	Embryonic defects and growth alteration in mice with homozygous disruption of the <i>Patz1</i> gene. Journal of Cellular Physiology, 2013, 228, 646-653.	4.1	29
30	Circulating immune biomarkers as predictors of the response to pembrolizumab and weekly low dose carboplatin and paclitaxel in NSCLC and poor PS: An interim analysis. Oncology Letters, 2019, 17, 1349-1356.	1.8	27
31	Role of PTPRJ genotype in papillary thyroid carcinoma risk. Endocrine-Related Cancer, 2010, 17, 1001-1006.	3.1	25
32	A novel fully human anti-NCL immunoRNase for triple-negative breast cancer therapy. Oncotarget, 2016, 7, 87016-87030.	1.8	23
33	Ran Binding Protein 9 (RanBP9) is a novel mediator of cellular DNA damage response in lung cancer cells. Oncotarget, 2016, 7, 18371-18383.	1.8	23
34	HMGA1 protein is a novel target of the ATM kinase. European Journal of Cancer, 2008, 44, 2668-2679.	2.8	22
35	The CTLH Complex in Cancer Cell Plasticity. Journal of Oncology, 2019, 2019, 1-13.	1.3	20
36	POZ-, AT-hook-, and Zinc Finger-containing Protein (PATZ) Interacts with Human Oncogene B Cell Lymphoma 6 (BCL6) and Is Required for Its Negative Autoregulation. Journal of Biological Chemistry, 2012, 287, 18308-18319.	3.4	16

DARIO PALMIERI

#	Article	IF	CITATIONS
37	The Eighth Fibronectin Type III Domain of Protein Tyrosine Phosphatase Receptor J Influences the Formation of Protein Complexes and Cell Localization. Journal of Biochemistry, 2009, 145, 377-385.	1.7	15
38	Impairment of the p27kip1 function enhances thyroid carcinogenesis in TRK-T1 transgenic mice. Endocrine-Related Cancer, 2009, 16, 483-490.	3.1	15
39	RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients. Oncogene, 2018, 37, 6463-6476.	5.9	15
40	B-RAF mutations are a rare event in pituitary adenomas. Journal of Endocrinological Investigation, 2007, 30, RC1-RC3.	3.3	12
41	The Mia/Cd-rap gene expression is downregulated by the high-mobility group A proteins in mouse pituitary adenomas. Endocrine-Related Cancer, 2007, 14, 875-886.	3.1	11
42	Scorpins in the DNA Damage Response. International Journal of Molecular Sciences, 2018, 19, 1794.	4.1	11
43	Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients. Pharmacogenomics and Personalized Medicine, 2013, 7, 1.	0.7	10
44	Genetic ablation of interacting with Spt6 (Iws1) causes early embryonic lethality. PLoS ONE, 2018, 13, e0201030.	2.5	9
45	Hmga1 null mice are less susceptible to chemically induced skin carcinogenesis. European Journal of Cancer, 2008, 44, 318-325.	2.8	7
46	NCL Inhibition Exerts Antineoplastic Effects against Prostate Cancer Cells by Modulating Oncogenic MicroRNAs. Cancers, 2020, 12, 1861.	3.7	6
47	Tagging enhances histochemical and biochemical detection of Ran Binding Protein 9 in vivo and reveals its interaction with Nucleolin. Scientific Reports, 2020, 10, 7138.	3.3	4
48	Editorial: From "Junk DNA―to Clinically Relevant Tools for Cancer Diagnosis, Staging, and Tailored Therapies: The Incredible Case of Non-Coding RNAs. Frontiers in Oncology, 2019, 9, 389.	2.8	2
49	Mass COVID-19 patient screening using UvsX and UvsY mediated DNA recombination and high throughput parallel sequencing. Scientific Reports, 2022, 12, 4082.	3.3	2
50	RANBP9 as potential therapeutic target in non-small cell lung cancer. Journal of Cancer Metastasis and Treatment, 2020, 2020, .	0.8	1
51	In silico study predicts a key role of <scp>RNA</scp> â€binding domains 3 and 4 in <scp>nucleolin–miRNA</scp> interactions. Proteins: Structure, Function and Bioinformatics, 2022, 90, 1837-1850.	2.6	1
52	POZ-, AT-hook-, and zinc finger-containing protein (PATZ) interacts with human oncogene B cell lymphoma 6 (BCL6) and is required for its negative autoregulation Journal of Biological Chemistry, 2014, 289, 14966.	3.4	0
53	In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation. Journal of Cell Biology, 2013, 201, i4-i4.	5.2	0
54	Gene-expression profiling of collecting duct carcinoma of the kidney Journal of Clinical Oncology, 2016, 34, 540-540.	1.6	0